Sonic Healthcare Ltd (ASX: SHL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sonic Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sonic Healthcare Ltd (ASX: SHL)
Latest News
Value Investing
Down more than 10% in 7 months, I'm backing these 3 ASX shares to reverse that — and then some! — by 2025
Share Market News
Here are the top 10 ASX 200 shares today
Healthcare Shares
2 popular ASX healthcare shares making news on Thursday
Healthcare Shares
Are Sonic Healthcare or CSL shares a better buy?
Dividend Investing
Have your ASX shares grown their dividend for 10 years in a row? These 2 stocks have
Share Market News
Here are the top 10 ASX 200 shares today
Opinions
After a 25% crash, is this ASX 200 stock in deep value territory?
How to invest
Investing in ASX shares? Why CEO pay DOES matter when misaligned
Dividend Investing
An ASX dividend titan I'd buy over BHP shares
Opinions
Which ASX shares to buy if interest rates rise (and which to avoid)
Dividend Investing
Passive income powerhouses! 3 ASX shares I'd consider buying for rising dividends
Healthcare Shares
Is the slashed Sonic Healthcare share price a 'buying opportunity'?
Frequently Asked Questions
-
Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.
-
Sonic Healthcare generally pays its shareholder dividends in March and September.
-
Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.
-
Sonic Healthcare Ltd listed on the ASX on 30 April 1987.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 03 Sep 2025 | $0.6300 | 35.00% | Final | 18 Sep 2025 |
| 05 Mar 2025 | $0.4400 | 0.00% | Interim | 20 Mar 2025 |
| 04 Sep 2024 | $0.6300 | 0.00% | Final | 19 Sep 2024 |
| 01 Mar 2024 | $0.4300 | 0.00% | Interim | 21 Mar 2024 |
| 06 Sep 2023 | $0.6200 | 100.00% | Final | 21 Sep 2023 |
| 07 Mar 2023 | $0.4200 | 100.00% | Interim | 22 Mar 2023 |
| 06 Sep 2022 | $0.6000 | 100.00% | Final | 21 Sep 2022 |
| 08 Mar 2022 | $0.4000 | 100.00% | Interim | 23 Mar 2022 |
| 07 Sep 2021 | $0.5500 | 65.00% | Final | 22 Sep 2021 |
| 09 Mar 2021 | $0.3600 | 30.00% | Interim | 24 Mar 2021 |
| 07 Sep 2020 | $0.5100 | 30.00% | Final | 22 Sep 2020 |
| 10 Mar 2020 | $0.3400 | 30.00% | Interim | 25 Mar 2020 |
| 10 Sep 2019 | $0.5100 | 30.00% | Final | 25 Sep 2019 |
| 08 Mar 2019 | $0.3300 | 20.00% | Interim | 26 Mar 2019 |
| 12 Sep 2018 | $0.4900 | 30.00% | Final | 27 Sep 2018 |
| 06 Mar 2018 | $0.3200 | 20.00% | Interim | 10 Apr 2018 |
| 08 Sep 2017 | $0.0000 | 0.00% | Final | 11 Oct 2017 |
| 07 Mar 2017 | $0.3100 | 20.00% | Interim | 11 Apr 2017 |
| 08 Sep 2016 | $0.4400 | 30.00% | Final | 27 Sep 2016 |
| 03 Mar 2016 | $0.3000 | 30.00% | Interim | 06 Apr 2016 |
| 05 Sep 2014 | $0.4000 | 55.00% | Final | 23 Sep 2014 |
| 03 Sep 2012 | $0.2923 | 53.88% | Final | 09 Oct 2012 |
| 04 Mar 2011 | $0.1881 | 35.62% | Interim | 24 Mar 2011 |
| 08 Sep 2010 | $0.2818 | 43.47% | Final | 28 Sep 2010 |
| 03 Mar 2010 | $0.1932 | 43.48% | Interim | 25 Mar 2010 |
| 08 Sep 2009 | $0.2818 | 43.47% | Final | 28 Sep 2009 |
| 05 Mar 2009 | $0.1936 | 68.18% | Interim | 26 Mar 2009 |
| 08 Sep 2008 | $0.3200 | 100.00% | Final | 09 Oct 2008 |
| 28 Feb 2006 | $0.1500 | 100.00% | Interim | 20 Mar 2006 |
| 31 Aug 2005 | $0.2300 | 100.00% | Final | 19 Sep 2005 |
| 26 Feb 2004 | $0.1000 | 100.00% | Interim | 17 Mar 2004 |
SHL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Sonic Healthcare Ltd
Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.
While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.
The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.
SHL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $23.03 | $0.20 | 0.88% | 1,496,665 | $22.88 | $23.22 | $22.85 |
| 12 Jan 2026 | $22.83 | $0.43 | 1.92% | 841,560 | $22.45 | $22.92 | $22.41 |
| 09 Jan 2026 | $22.40 | $0.07 | 0.31% | 743,099 | $22.44 | $22.63 | $22.35 |
| 08 Jan 2026 | $22.33 | $0.19 | 0.86% | 761,136 | $22.07 | $22.41 | $22.04 |
| 07 Jan 2026 | $22.14 | $0.24 | 1.10% | 736,678 | $22.00 | $22.28 | $21.98 |
| 06 Jan 2026 | $21.90 | $-0.32 | -1.44% | 1,049,728 | $22.24 | $22.26 | $21.76 |
| 05 Jan 2026 | $22.22 | $-0.22 | -0.98% | 602,816 | $22.50 | $22.60 | $22.22 |
| 02 Jan 2026 | $22.44 | $-0.17 | -0.75% | 431,186 | $22.61 | $22.62 | $22.41 |
| 31 Dec 2025 | $22.61 | $0.16 | 0.71% | 868,051 | $22.46 | $22.61 | $22.30 |
| 30 Dec 2025 | $22.45 | $-0.19 | -0.84% | 787,164 | $22.63 | $22.73 | $22.36 |
| 29 Dec 2025 | $22.64 | $0.07 | 0.31% | 544,514 | $22.65 | $22.68 | $22.48 |
| 24 Dec 2025 | $22.57 | $-0.23 | -1.01% | 452,233 | $22.79 | $22.84 | $22.51 |
| 23 Dec 2025 | $22.80 | $0.25 | 1.11% | 887,225 | $22.70 | $22.85 | $22.52 |
| 22 Dec 2025 | $22.55 | $-0.03 | -0.13% | 1,016,065 | $22.53 | $22.82 | $22.48 |
| 19 Dec 2025 | $22.58 | $0.06 | 0.27% | 4,663,880 | $22.60 | $22.61 | $22.36 |
| 18 Dec 2025 | $22.52 | $0.00 | 0.00% | 1,995,229 | $22.72 | $22.72 | $22.40 |
| 17 Dec 2025 | $22.52 | $-0.46 | -2.00% | 1,849,309 | $23.11 | $23.24 | $22.30 |
| 16 Dec 2025 | $22.98 | $0.00 | 0.00% | 1,340,815 | $23.10 | $23.11 | $22.92 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Nov 2025 | Christopher Wilks | Issued | 34,170 | $780,442 |
Director remuneration. 1,04,898 Rights
|
| 20 Nov 2025 | Christopher Wilks | Issued | 233,760 | $5,339,078 |
Director remuneration.
|
| 20 Nov 2025 | James Newcombe | Issued | 345,342 | $7,887,611 |
Director remuneration.
|
| 20 Nov 2025 | James Newcombe | Issued | 50,481 | $1,152,986 |
Director remuneration. 50,481 Rights
|
| 18 Nov 2025 | Colin Goldschmidt | Expiry | 321,637 | $6,718,996 |
Options expired. As per announcement on 21-11-2025
|
| 18 Nov 2025 | Christopher Wilks | Expiry | 122,570 | $2,560,487 |
Options expired.
|
| 16 Oct 2025 | Nicola Wakefield Evans | Buy | 2,500 | $54,450 |
On-market trade.
|
| 15 Oct 2025 | Katharine Giles | Buy | 1,000 | $21,169 |
On-market trade.
|
| 03 Oct 2025 | Katharine Giles | Buy | 1,000 | $21,720 |
On-market trade.
|
| 02 Oct 2025 | Mark Compton | Buy | 1,500 | $32,355 |
On-market trade.
|
| 01 Oct 2025 | Christine Bennett | Buy | 1,100 | $23,661 |
On-market trade.
|
| 26 Sep 2025 | Kathryn (Kate) Spargo | Buy | 3,500 | $74,421 |
On-market trade.
|
| 26 Sep 2025 | Suzanne Crowe | Buy | 2,365 | $49,948 |
On-market trade.
|
| 02 Sep 2025 | Colin Goldschmidt | Exercise | 9,852 | $233,985 |
Conversion of securities. 172,148 - performance rights
|
| 02 Sep 2025 | Colin Goldschmidt | Buy | 9,852 | $233,985 |
Conversion of securities.
|
| 02 Sep 2025 | Christopher Wilks | Exercise | 3,754 | $89,157 |
Conversion of securities. 72,240 performance rights
|
| 02 Sep 2025 | Christopher Wilks | Buy | 3,754 | $89,157 |
Conversion of securities.
|
| 09 Apr 2025 | Christine Bennett | Buy | 1,000 | $25,000 |
On-market trade.
|
| 08 Apr 2025 | Katharine Giles | Buy | 850 | $21,012 |
On-market trade. As per announcement on 08/04/2025.
|
| 25 Mar 2025 | Nicola Wakefield Evans | Buy | 2,000 | $51,200 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Christopher David Wilks | Chief Financial OfficerFinance Director | Dec 1989 |
Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. He was previously a partner in a private investment bank.
|
| Mr Mark Raymond Compton | Non-Executive DirectorNon-Executive Chairman | Oct 2014 |
Prof Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management at Macquarie University, Nonexecutive Director of The Hospitals Contribution Fund of Australia and Nonexecutive Chairman of not for profit organisations St Lukes Care and the Order of St John. He was also Chairman of the Woolcock Institute of Medical Research, Nonexecutive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia. In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017, and was appointed as a Member of the Order of Australia (AM) in January 2010.
|
| Mr Neville Mitchell | Non-Executive Director | Sep 2017 |
Mr Mitchell has international healthcare and finance experience. He has also performed roles with a number of industry and government committees. He is a member of the Risk Management Committee.
|
| Professor Suzanne Crowe | Non-Executive Director | Apr 2020 |
Professor Crowe is an Emeritus Professor of Medicine at Monash University, Melbourne. She was a Nonexecutive Director of St Vincents Health Australia Ltd. She retired from Burnet Institute as Associate Director in 2018 following a 30 year research career, having played an integral role in Burnets development as a global research organisation. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne. She has served as a Member of the Prime Ministers Science Engineering and Innovation Council, as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. She was appointed a Fellow of the Australian Academy of Health and Medical Sciences in 2015, and an Officer of the Order of Australia (AO) in 2020, in recognition of her distinguished service to health and aged care administration, clinical governance, biomedical research, and to education. She is Chair of the Risk Management Committee.
|
| Professor Christine Constance Bennett | Non-Executive Director | Sep 2022 |
Professor Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. She is an experienced nonexecutive director in forprofit and social enterprises, Patron of Research Australia, Convenor of the Champions of Change Health Coalition STEM and Health Group for gender equality, and a member of Chief Executive Women. She is also an advisor to the Digital Health Cooperative Research Centre and in 2024 completed a certificate on AI Ethics and Board Oversight. Her previous Board nonexecutive director roles include Telstra Health, HeartWare Limited, Symbion Health Limited and Chair of Sydney Childrens Hospital Network. In December 2021, she retired from and was awarded Emeritus Professor by The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships and Dean, School of Medicine, Sydney for over ten years. Her prior experience has included being Group Executive and Chief Medical Officer for MBF and then Bupa Health and Care Services; CEO and later Chair of Research Australia; Managing Director of Total Health Enterprise Ltd; Partner in Health and Life Sciences for KPMG Australia; CEO of Westmead Hospital and Community Health Services; General Manager for the Royal Hospital for Women; and Head of Planning in NSW Health. She has an active commitment to and involvement in medical professional issues, public policy and medical research. In 2008 she was appointed as Chair of the National Health and Hospitals Reform Commission producing a longterm blueprint for reform of health and aged care in Australia. She was awarded an Officer of the Order of Australia (AO) in the 2014 Australia Day Honours in recognition of her distinguished service to medicine and health care leadership. She is a member of the Risk Management Committee.
|
| Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Jul 2010 |
Ms Spargo has gained broad business experience as both a legal advisor, having worked in private practice and government, and as a director. She has been a director of both listed and unlisted companies for more than 20 years. She also holds nonexecutive director roles with CIMIC Group Limited, the Future Fuels Cooperative Research Centre and Geelong Football Club Limited. She was previously a Nonexecutive Director of Fletcher Building Limited, Xenith IP Group Limited, Adairs Limited and Sigma Healthcare Limited.
|
| Ms Nicola Wakefield Evans | Non-Executive Director | Feb 2025 |
Ms Evans is a highly experienced nonexecutive director and business leader. Over a 35 year international career, she has gained a broad range of commercial, business management, strategy and legal experience in the financial services, health, energy and infrastructure sectors. She was a corporate advisory partner at King & Wood Mallesons for more than 20 years and also held several key management positions at the firm including Managing Partner International in Hong Kong and Managing Partner, Practice in Sydney. She is currently a member of the Australia Future Fund Board of Guardians. She is also Chair of MetLife Australia and a panel member of the Australian Governments Takeovers Panel. In 2019 she was invited by the Australian Government to be a member of the Australian delegation to the United Nations Commission on the Status of Women. She is a member of Chief Executive Women, and in 2023 was appointed as a Member of the Order of Australia (AM) in recognition of significant service to business, the law, and diversity.
|
| Dr Katharine Giles | Non-Executive Director | Sep 2022 |
Dr Giles is a registered medical practitioner with the Medical Board of Australia. After initially practicing as a medical doctor, she moved to commercial pursuits which combined science, medicine and health. She is currently Managing Director and Chief Executive Officer of OncoRes Medical, which is developing novel imaging technology to improve cancer outcomes. She is also a Venture Partner at Brandon Capital Partners, a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed to earlystage technology investment, and a Founding Director of the Australian Governments National Reconstruction Fund Corporation. She has startup experience in medical apps, diagnostics and fitness devices and has served on the boards of private health care related technology companies. She is a member of the Curtin University Commercialisation Advisory Board
|
| Mr James Pacey Newcombe | Non-Executive Director | Nov 2025 |
--
|
| Mr Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
|
| Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 151,482,588 | 30.65% |
| J P Morgan Nominees Australia Pty Limited | 62,585,186 | 12.66% |
| Citicorp Nominees Pty Limited | 56,792,007 | 11.49% |
| Jardvan Pty Ltd | 15,109,474 | 3.06% |
| Gekramon Investment GmbH & Co. KG | 13,802,416 | 2.79% |
| BNP Paribas Noms Pty Ltd | 8,357,561 | 1.69% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 6,146,467 | 1.24% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 5,386,200 | 1.09% |
| Argo Investments Limited | 4,226,053 | 0.86% |
| National Nominees Limited | 3,981,193 | 0.81% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,846,986 | 0.78% |
| HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> | 3,432,756 | 0.69% |
| Australian Foundation Investment Company Limited | 3,159,672 | 0.64% |
| Netwealth Investments Limited <Super Services A/C> | 1,907,879 | 0.39% |
| Anton-Martin Familienstiftung<Anton-Martin Foundation A/C> | 1,864,163 | 0.38% |
| Blaise Mentha | 1,850,000 | 0.37% |
| Polly Pty Ltd <A/C Patterson Family> | 1,817,416 | 0.37% |
| IOOF Investment Services Limited <IPS Superfund A/C> | 1,758,380 | 0.36% |
| Quintal Pty Ltd <Harken Family A/C> | 1,587,908 | 0.32% |
| BKI Investment Company Limited | 1,462,000 | 0.29% |